The Summary
In this 52-week randomized, double-blind, placebo-controlled trial, 55 patients with suspected at-risk metabolic dysfunction-associated steatohepatitis (MASH) received either weekly semaglutide (2.4 mg) or a placebo. Researchers used non-invasive tests, including ultrasound liver scans and FAST scores, to assess eligibility and track progress. The semaglutide group showed a significantly greater reduction in FAST scores (-0.28 vs. -0.12) and a 30% or greater reduction in liver fat for 60% of participants, alongside decreased liver enzymes and LDL cholesterol compared to the placebo group.
Why this is interesting
Historically, diagnosing and monitoring severe fatty liver disease (MASH) required painful, risky liver biopsies. This study is exciting because it proves that simple, non-invasive imaging and blood tests can reliably identify eligible patients and accurately track their liver recovery. For patients, this means managing a serious liver condition could soon involve far fewer needles and outpatient procedures. Additionally, it confirms semaglutide's therapeutic benefits extend directly to protecting liver tissue and reversing inflammation.